In March 2025, the pharmaceutical company Farmak successfully completed the re-confirmation procedure of the World Health Organization (WHO) prequalification for one of its injectable medicines. This product is used in the treatment of severe inflammatory, allergic, and immune diseases, as well as in emergency therapy. The medicine first received WHO prequalification in 2020.
WHO prequalification of medicines is a comprehensive procedure that evaluates their quality, safety, and efficacy. Obtaining prequalification confirms compliance with international standards and enables the medicine to be used in global healthcare programs, including centralized procurement by UNICEF and other international organizations.
Farmak is the leader of the Ukrainian pharmaceutical market. The company exports its products to more than 60 countries worldwide* and has a portfolio of over 450 medicinal products. All medicines are manufactured in compliance with European GMP standards. Each year, up to 90% of Farmak’s profit is reinvested in development: research and drug development, new manufacturing facilities, and technologies.
*Refers to exports carried out in the period 2020–2025.
